Aurion Biotech is a privately held, clinical-stage biotech company, whose mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion Biotech completed a $120M Series C financing in 2022, and they are the recipient of the prestigious Prix Galien award for best start-up in biotech. Their lead candidate, AURN001, is in Phase 1/2 trials in the U.S. and Canada for the treatment of corneal edema secondary to corneal endothelial disease. This is the first allogenic, clinically validated cell therapy for corneal endothelial disease, having received regulatory approval in Japan. Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.